Fabrizio Kevin, Groner Abraham, Boes Marianne, Pirofski Liise-anne
Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Clin Vaccine Immunol. 2007 Apr;14(4):382-90. doi: 10.1128/CVI.00374-06. Epub 2007 Feb 14.
Antibody-based approaches to pneumococcal disease may hold promise for immunocompromised patients in whom vaccines are less immunogenic and/or in the context of antimicrobial resistance. Antibody-mediated protection against experimental pneumococcal pneumonia has been shown to depend on immunoregulation, but the relationship between antibody and protection against pneumococcal sepsis and immunoregulation has not been examined. Similarly, the requirement for B and T cells for antibody efficacy is not known. In this study, we determined the efficacy of the human pneumococcal capsular polysaccharide serotype 3-specific antibody, A7 (immunoglobulin M [IgM]), in secretory IgM (sIgM)(-/-), CD4(-/-), CD8(-/-), muMT(-/-), and SCID mice and investigated its effect on cytokine and chemokine expression in sera and spleens from mice with intact cellular immunity. A7 is known to be protective against systemic infection with serotype 3 and to require complement for efficacy. Compared to that of an isotype control antibody, A7 administration prolonged the survival of mice of each immunodeficient strain and was associated with a significant reduction in CFU in blood, lung, and spleen samples and a significantly reduced level of keratinocyte-derived chemokine (KC), interleukin-6 (IL-6), and macrophage inflammatory protein-2 (MIP-2) expression in normal and sIgM(-/-) mice. Studies with mice treated with penicillin revealed similar reductions in CFU and similar levels of IL-6, KC, or MIP-2 expression in A7- and penicillin-treated mice. These findings demonstrate that natural IgM and B and T cells are dispensable for A7-mediated protection against experimental pneumococcal sepsis and suggest that the efficacy of antibody-mediated protection depends on immunomodulation. Taken together, our data extend the association between antibody-mediated protection and immunomodulation to protection against systemic pneumococcal infection and to a clinically important serotype often responsible for pneumococcal sepsis.
基于抗体的肺炎球菌疾病治疗方法可能为免疫功能低下的患者带来希望,这些患者接种疫苗后免疫原性较低,和/或处于抗菌药物耐药的情况下。抗体介导的对实验性肺炎球菌肺炎的保护作用已被证明取决于免疫调节,但抗体与预防肺炎球菌败血症及免疫调节之间的关系尚未得到研究。同样,B细胞和T细胞对抗体疗效的必要性也尚不清楚。在本研究中,我们测定了人肺炎球菌荚膜多糖3型特异性抗体A7(免疫球蛋白M [IgM])在分泌型IgM(sIgM)基因敲除小鼠、CD4基因敲除小鼠、CD8基因敲除小鼠、μMT基因敲除小鼠和重症联合免疫缺陷(SCID)小鼠中的疗效,并研究了其对细胞免疫功能正常的小鼠血清和脾脏中细胞因子及趋化因子表达的影响。已知A7对3型全身性感染具有保护作用,且其发挥疗效需要补体参与。与同型对照抗体相比,给予A7可延长各免疫缺陷品系小鼠的存活时间,并使血液、肺和脾脏样本中的菌落形成单位(CFU)显著减少,同时使正常小鼠和sIgM基因敲除小鼠中角质形成细胞衍生趋化因子(KC)、白细胞介素-6(IL-6)和巨噬细胞炎性蛋白-2(MIP-2)的表达水平显著降低。用青霉素治疗小鼠的研究显示,A7治疗组和青霉素治疗组小鼠的CFU减少程度相似,IL-6、KC或MIP-2的表达水平也相似。这些发现表明,天然IgM以及B细胞和T细胞对于A7介导的预防实验性肺炎球菌败血症并非必需,并提示抗体介导的保护作用的疗效取决于免疫调节。综上所述,我们的数据将抗体介导的保护作用与免疫调节之间的关联扩展至预防全身性肺炎球菌感染以及一种临床上重要的、常导致肺炎球菌败血症的血清型。